Publication | Closed Access
LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
23
Citations
0
References
2020
Year
Metastatic Cervical CancerCervical CancerPhase IiMedicineCancer ManagementImmunologyPathologyLba32 Tisotumab VedotinCancer TreatmentOncologyRadiation Oncology
No additional data available for this publication yet. Check back later!